Dr. Ayaka Nishikawa, Chief Director of Dermatology at Shonan Beauty Clinic, presented her research findings at the International Medical Conference “ASLS KOREA.”
Contributed to the academic advancement of aesthetic medicine through a comparative clinical study exploring the optimal RF treatment for the lower eyelid.
IRVINE, Calif --SBC Medical Group Holdings Incorporated (Nasdaq: SBC) a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that Dr. Ayaka Nishikawa, Chief Director of Dermatology at Shonan Beauty Clinic, presented her research findings at the “ASLS KOREA 2025 Autumn Congress.”
ASLS (Aesthetic Surgery & Laser Society) is an international aesthetic medicine conference originating in Korea, where the world's leading specialists in the field gather to share cutting-edge knowledge and techniques. Dr. Nishikawa was highly recognized for his previous conference presentations and extensive clinical experience. She presented at the “ASLS KOREA 2025 Autumn Congress,” held over two days starting Saturday, October 11, 2025, in Seoul, South Korea.
At this conference, she presented on the optimal selection method for RF (radiofrequency) treatment in lower eyelid tightening, based on extensive clinical data and comparative verification results. She clinically compared multiple RF modalities (devices and output characteristics) and presented a scientific approach to derive the most effective and safest treatment method tailored to each patient's unique skin characteristics and treatment goals. Her presentation proposed clear, evidence-based decision criteria for treatment selection. This presentation strongly emphasized that aesthetic medicine is not merely about improving appearance but is a medical practice that enhances QOL (Quality of Life) based on “medical judgment” tailored to each individual's condition. This practical and scientific communication garnered significant interest from physicians and researchers from around the world gathered at the venue, resulting in international attention and recognition within the field of comparative treatment technology research.
In recent years, technological innovation has advanced in the field of aesthetic medicine, increasing the importance of disseminating specialized knowledge and fostering international collaboration beyond the clinical setting. To meet diversifying needs, introducing cutting-edge technology is essential, alongside a global perspective and flexible thinking. SBC Medical Group will continue to contribute to the sustainable development of aesthetic medicine by sharing its pioneering initiatives globally through exchanges at international conferences and with overseas research institutions.
Event Overview: “ASLS KOREA 2025 Autumn Congress”
Venue: COEX Convention Center, Hall C (Seoul, South Korea)
Dates: October 11 (Sat) – October 12 (Sun), 2025
Official Website: https://www.asls.kr
Presentation Title
How to Choose the Optimal RF Modality for Lower Eyelid Tightening: A Comparative Clinical Approach
After graduating from Yokohama City University School of Medicine, Dr. Ayaka Nishikawa joined Shonan Beauty Clinic in 2015 as an aesthetic dermatologist. In 2018, she was appointed Chief Director of Dermatology, overseeing all dermatology departments across the organization. Currently, she plays a key role in the SBC Medical Group, leading initiatives in treatment development, technical education for physicians and nurses, and safety management in the field of aesthetic dermatology. Through the analysis of clinical cases, she is dedicated to promoting evidence-based medicine and actively engages in academic activities such as presentations at international conferences and research publications. In recognition of her achievements, Dr. Nishikawa was appointed Visiting Professor at SBC Tokyo Medical University in 2023.
For more information about Dr. Nishikawa’s profile, please visit [here].
About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a comprehensive medical group operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, AGA (hair restoration), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com/
Contacts
SBC Medical Group Holdings Incorporated (Asia)
Hikaru Fukui / Head of Investor Relations E-mail: ir@sbc-holdings.com